NCT06768177

Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · Academic / Other
• Sex: Male
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

Patients are randomized into 2 groups (A and B), subsequently group A is subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP while group B is subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg. After 4 (four) weeks the groups will be crossed, so group A will be subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg while group B will be subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP.

Conditions

• Erectile Dysfunction Due to General Medical Condition
• Erectile Dysfunction Following Radical Prostatectomy
• Erectile Dysfunction Associated With Type 2 Diabetes Mellitus
• Erectile Dysfunctions

Interventions

Type	Name	Description
DRUG	PRP injection	3 ML OF PRP
DRUG	Alprostadil 20 micrograms	1 ML

Timeline

• Start date: 2023-04-01
• Primary completion: 2024-11-01
• Completion: 2025-11-01
• First posted: 2025-01-10
• Last updated: 2025-10-02

Locations

1 site across 1 country: Italy